Fig. 4: Decision tree on how to tailor the treatment regimen according to MNV subtype. | Eye

Fig. 4: Decision tree on how to tailor the treatment regimen according to MNV subtype.

From: Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes

Fig. 4

*Fixed should not be the treatment regimen of choice but can be used in some instances where T&E is not feasible due to resource or organisational constraints. MNV macular neovascularisation, PRN pro re nata (as needed), q12w once every 12 weeks, T&E treat-and-extend.

Back to article page